Evaluation of the possibility to increase the in vivo production of hematopoietic stem cells, endothelial progenitors and
mesenchymal stromal cells by  intra-medullary injection of platelet rich plasma (PRP) with recombinant soluble human tissue factor. This
would have important clinical repercussions both in hematology, orthopedics, cardiology and tissue engineering. This procedure
should allow to avoid intensive manipulations of cells and  progressive loss of their characteristics. Optimization of extraction
methods, purification and tissue reconstruction starting with stromal cells from adipose tissue. Evaluation of umbilical cord
(wharton's jelly) as mesenchymal stromal cell source: collection, isolation, characterisation and capacities to sustain hematopoiesis.
Applicability as adjuvents for human cell transplantation.